A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Trial Profile

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOR
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2018 According to a Amgen media release, the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS (carfilzomib).
    • 12 Jan 2018 Planned End Date changed from 1 Dec 2018 to 30 Jan 2018.
    • 12 Dec 2017 Results (n=303) of a biomarker substudy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top